Previous close | 34.00 |
Open | 34.52 |
Bid | 33.88 x 0 |
Ask | 34.00 x 0 |
Day's range | 33.74 - 35.00 |
52-week range | 4.13 - 40.90 |
Volume | |
Avg. volume | 586,314 |
Market cap | 993.013M |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.33 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 04 Nov 2019 |
1y target est | 23.00 |
Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025.
Moberg Pharma AB (OMX: MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.